COVID-19 Therapeutics: US FDA Wants Sponsors To Use The Pre-IND Route, Not The Pre-EUA Path

 
• By Sue Sutter
  
good better best
A pre-IND meeting request is the best route for sponsors to talk to US FDA about potential COVID-19 therapeutics. • Source: Shutterstock

More from Clinical Trials

More from R&D